Article

CMS Delays 5010 Enforcement, Again

The CMS will not begin enforcing the mandated move to Version 5010 transaction standards for an additional three months, until after June 30.

The deadline for the switch to the 5010 standards was Jan. 1. In November, the CMS announced that although it was not changing the actual deadline for complying with the standards, it would not initiate enforcement action until March 31.

Read the full story: http://hcp.lv/AtX3iw

Source: ModernHealthcare.com

Related Videos
Eboni Price-Haywood, MD, and Toni Flowers, PhD
Tom Belmon, CAP, GPBCH
CK Wang, MD, COTA
John Barkett, MBA
1 expert in this video
1 expert in this video
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Related Content
AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com
May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD
Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
managed care cast logo
May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS
Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com
May 16th 2025

Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

AJMC Contributor
A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Managed Care Cast
May 9th 2025

Frameworks for Advancing Health Equity: Food as Medicine

Giuliana Grossi Colleen Ereditario, MPH, RD, LDN
Learn about how Allegheny Health Network's "Food as Medicine" initiative tackles food insecurity and enhances health through personalized nutrition support.
Obesity highlighted on page | Image credit: Feng Yu – stock.adobe.com
May 16th 2025

5 Ways the US Obesity Landscape Strays From the Global Picture

Hayden E. Klein
While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial saturation, access, and long-term care distinct from other parts of the world.
Patients with relapsed/refractory disease achieved an ORR of 63% in the phase 2 study. | Image Credit: Eleni - stock.adobe.com
May 16th 2025

Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS

Courtney Flaherty
The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo